GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSN) » Definitions » Total Liabilities

NeuroSense Therapeutics (NeuroSense Therapeutics) Total Liabilities : $5.05 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Total Liabilities?

NeuroSense Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was $5.05 Mil.

NeuroSense Therapeutics's quarterly Total Liabilities declined from Jun. 2023 ($9.41 Mil) to Sep. 2023 ($5.58 Mil) and declined from Sep. 2023 ($5.58 Mil) to Dec. 2023 ($5.05 Mil).

NeuroSense Therapeutics's annual Total Liabilities declined from Dec. 2021 ($2.43 Mil) to Dec. 2022 ($2.09 Mil) but then increased from Dec. 2022 ($2.09 Mil) to Dec. 2023 ($5.05 Mil).


NeuroSense Therapeutics Total Liabilities Historical Data

The historical data trend for NeuroSense Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics Total Liabilities Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
0.04 0.12 2.43 2.09 5.05

NeuroSense Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.09 2.45 9.41 5.58 5.05

NeuroSense Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

NeuroSense Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.459+(0.073+1.518
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=5.05

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=3.176--1.874
=5.05

NeuroSense Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.459+(0.073+1.518
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=5.05

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=3.176--1.874
=5.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeuroSense Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11 HaMenofim Street, Building B, Herzliya, ISR, 4676670
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.